· Published by Health Canada · Official notice
July 29, 2002
Health Canada has become aware of information issued by the US-FDA concerning a possible association between cochlear implants and the occurrence of bacterial meningitis . It was stated in the FDA Public Health Web Notification on July 24/2002 ( http://www.fda.gov/cdrh/safety/cochlear.html ).
"At least 25 cases of meningitis have been diagnosed worldwide in children and adults ranging in age from 21 months to 63 years who have undergone cochlear implantation for severe to profound deafness. A total of 9 known deaths resulted from these cases. At this time, 2 out of 3 companies have reported cases of bacterial meningitis in patients who have been implanted.
Cerebrospinal fluid culture results are available in 11 cases. Seven have grown Pneumococcus and four have grown Diplococci (most likely Pneumococcus). The vaccination history against Pneumococcus was available in 5 cases and none had been vaccinated. The onset of meningitis symptoms ranged from less than 24 hours to greater than 5 years from time of implant."
In Canada, one case of meningitis (not resulting in death) has been reported in a patient with a cochlear implant. Health Canada is following up with all the manufacturers of cochlear implants distributed in Canada. Health Canada is also conducting an investigation to determine if there are other cases of meningitis associated with cochlear implants in Canada.
Cochlear implants are devices containing electrodes which are positioned in the cochlea (inner ear) to activate auditory nerve fibers allowing for transmission of sound signals to the brain. Approximately 60,000 implantations have been performed worldwide to date.
Meningitis is an inflammation of the lining of the surface of the brain which is often the result of a bacterial or viral infection. Early symptoms of meningitis include fever, irritability, lethargy and loss of appetite in infants and young children. Older children and adults may also manifest headache, stiff neck, photophobia, nausea and vomiting, and confusion or alteration in consciousness. Physicians are encouraged to consider a diagnosis of meningitis in cochlear implant patients when such symptoms exist and to begin appropriate diagnosis and treatment as soon as possible. Children under 2 years of age have the highest risk of developing meningitis.
A small percentage of deaf patients may have congenital abnormalities of the inner ear which predispose them to meningitis even prior to implantation. Other predisposing factors may include otitis media, immunodeficiency status, prior history of meningitis, or neuro-surgical intervention. The cochlear implant, because it is a foreign body, may act as a nidus for infection when patients have bacterial illnesses.
In some of the reported cases of meningitis in cochlear implant recipients, patients may have had overt or sub-clinical otitis media prior to surgery or before the meningitis developed. Physicians are encouraged to consider prophylactic antibiotic treatment prior to implantation, as appropriate, and to diagnose and treat otitis media promptly in patients with cochlear implants.
Cochlear implant candidates, as well as those individuals who have already received the implant, may benefit from immunizations against organisms that commonly cause bacterial meningitis, particularly Streptococcus pneumoniae. All candidates for and recipients of cochlear implants should be up-to-date with their immunizations.
The National Advisory Committee on Immunization (NACI) recommends the following:
Pneumococcal vaccines
Haemophilus vaccines
Meningococcal vaccines
For more details re: scheduling of doses and risk factor information, please consult the Canadian Immunization Guide, 6th edition, 2002 (http://www.phac-aspc.gc.ca/publicat/cig-gci/pdf/cdn_immuniz_guide-2002-6.pdf) or your local Medical Officer of Health.
As a reminder, all cases of bacterial meningitis are notifiable and should be promptly reported to your local Medical Officer of Health. Also, please report cases of meningitis in cochlear implant recipients directly to the device manufacturer or to Health Canada/ Health Products and Food Branch Inspectorate at the Operational Centre closest to you:
Health Products and Food Branch Inspectorate Operational Centres
Atlantic
Suite 1625, 1505 Barrington St.
Halifax, Nova Scotia
B3J 3Y6
Tel: (902) 426-5350
Fax: (902) 426-6676
Manitoba and Saskatchewan
510 Lagimodière Blvd.
Winnipeg, Manitoba
R2J 3Y1
Tel: (204) 983-5453
Fax: (204) 984-2155
Québec
1001 ouest, rue St-Laurent
Longueuil, Québec
J4K 1C7
Tel: (450) 646-1353, ext. 232
Fax: (450) 928-4455
Western
3155 Willingdon Green
Burnaby, BC
V5G 4P2
Tel: (604) 666-3704
Fax: (604) 666-3149
Ontario
2301 Midland Avenue
Scarborough, Ontario
M1P 4R7
Tel: (416) 973-1466
Fax: (416) 973-1954